Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | ALPI | P09923 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | XIAP | P98170 | 1/20 | 0.58 |
| ▸ | NOS3 | P29474 | 3/20 | 0.57 |
| ▸ | NOS1 | P29475 | 3/20 | 0.57 |
| ▸ | NOS2 | P35228 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | MPO | P05164 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.50 |
| ▸ | PPARA | Q07869 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29400473 | 1.00 | SLC7A5 (0.58) | SLC7A5PKMALPIPTGS1XIAP | |
| SCHEMBL1250588 | 1.00 | SLC7A5 (0.58) | SLC7A5PKMALPIPTGS1XIAP | |
| SCHEMBL43301 | 1.00 | SLC7A5 (0.58) | SLC7A5PKMALPIPTGS1XIAP | |
| SCHEMBL13971424 | 0.86 | SLC7A5 (0.69) | SLC7A5PKMALPIPTGS1XIAP | |
| SCHEMBL9164980 | 0.86 | SLC7A5 (0.69) | SLC7A5PKMALPIPTGS1XIAP | |
| SCHEMBL5301987 | 0.86 | NOS3 (0.50) | SLC7A5PKMALPIPTGS1XIAP | |
| SCHEMBL2152873 | 0.85 | NOS3 (0.45) | SLC7A5PKMALPIPTGS1XIAP | |
| SCHEMBL2152875 | 0.85 | NOS3 (0.45) | SLC7A5PKMALPIPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL9169793 | 0.84 | SLC7A5 (0.67) | SLC7A5PKMALPIPTGS1XIAP | |
| SCHEMBL22289236 | 0.83 | NOS3 (0.48) | SLC7A5PKMALPIPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1595 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590137-B2 | Meditope-enabled T cells | CITY OF HOPE (US) | 2026-03-31 | — | — | US | claimed |
| US-20250066418-A1 | CYSTEINE PEPTIDE-ENABLED ANTIBODIES | CITY OF HOPE | 2025-02-27 | — | — | US | claimed |
| US-20240425584-A1 | MECHANICALLY INTERLOCKING COMPLEXES | CITY OF HOPE | 2024-12-26 | — | — | US | claimed |
| CN-118767648-A | System for storing carbon dioxide, application and carbon dioxide storage and transportation method | 中国石油化工股份有限公司 | 2024-10-15 | — | — | CN | claimed |
| CN-114457049-B | Pyrrolysiyl-tRNA synthetase mutant and application thereof | 浙江大学杭州国际科创中心 | 2024-09-24 | — | — | CN | claimed |
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ZEALAND PHARMA A/S (DK) | 2024-09-03 | — | — | US | claimed |
| US-11897952-B2 | Mechanically interlocking complexes | CITY OF HOPE | 2024-02-13 | — | — | US | claimed |
| CN-117442748-A | Multivalent mimotopes, mimotope binding antibodies and uses thereof | 希望之城公司 | 2024-01-26 | — | — | CN | claimed |
| US-20230406884-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ZEALAND PHARMA A/S (DK) | 2023-12-21 | — | — | US | claimed |
| US-20230391887-A1 | MULTIVALENT MEDITOPES, MEDITOPE-BINDING ANTIBODIES AND USES THEREOF | HOPE CITY (US) | 2023-12-07 | — | — | US | claimed |
| EP-2069518-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE PHENYLALANINE COMPOUNDS FROM CINNAMIC ACID DERIVATIVES EMPLOYING A PHENYLALANINE AMMONIA LYASE DERIVED FROM IDIOMARINA LOIHIENSIS | DSM IP ASSETS BV (NL) | 2010-02-03 | — | — | EP | claimed |
| US-7576175-B2 | Amino acid terminated diphenylurea derivatives; display high binding affinity, specificity, and stability; use in treating cancer, inflammatory diseases, and autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-08-18 | — | — | US | claimed |
| US-7399619-B2 | Site specific incorporation of heavy atom-containing unnatural amino acids into proteins for structure determination | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-07-15 | — | — | US | claimed |
| WO-2008031016-A2 | HETEROCYCLIC LIGANDS FOR INTEGRIN IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-03-13 | — | — | WO | claimed |
| EP-1774018-A2 | SITE SPECIFIC INCORPORATION OF HEAVY ATOM-CONTAINING UNNATURAL AMINO ACIDS INTO PROTEINS FOR CRYSTAL STRUCTURE DETERMINATION | The Scripps Research Institute (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2005122379-A9 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | UNIV CALIFORNIA (US) | 2006-03-09 | — | — | WO | claimed |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-01-26 | — | — | US | claimed |
| WO-2005122379-A2 | ALPHA-4 BETA-1 INTEGRIN LIGANDS FOR IMAGING AND THERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-22 | — | — | WO | claimed |
| US-20050272121-A1 | Translation system including an orthogonal aminoacyl-transfer RNA synthetase with a specific sequence that preferentially aminoacylates an orthogonal transfer RNA with a brominated or iodinated phenylalanine or tyrosine | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-12-08 | — | — | US | claimed |
| WO-2005116237-A2 | SITE SPECIFIC INCORPORATION OF HEAVY ATOM-CONTAINING UNNATURAL AMINO ACIDS INTO PROTEINS FOR CRYSTAL STRUCTURE DETERMINATION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2005-12-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391887-A1 | MULTIVALENT MEDITOPES, MEDITOPE-BINDING ANTIBODIES AND USES THEREOF | FCGR3B, FCGR2A, CD47 | SLC7A5 3511/4885PKM 3363/4885ALPI 1470/4885 |
| US-11897952-B2 | Mechanically interlocking complexes | FCGR3B, FCGR2A, FCGRT | SLC7A5 2742/4885PKM 3560/4885ALPI 4028/4885 |
| US-20250066418-A1 | CYSTEINE PEPTIDE-ENABLED ANTIBODIES | LNPEP, CSTB, PTMS | SLC7A5 305/4885PKM 4362/4885ALPI 4850/4885 |
| US-20050272121-A1 | Translation system including an orthogonal aminoacyl-transfer RNA synthetase with a specific sequence that preferentially aminoacylates an orthogonal transfer RNA with a brominated or iodinated phenylalanine or tyrosine | AARS1, NSUN3, TARBP1 | SLC7A5 63/4885PKM 3547/4885ALPI 4410/4885 |
| US-20060019900-A1 | Alpha-4 beta-1 integrin ligands for imaging and therapy | ITGA4, ITGB4, ITGA1 | SLC7A5 576/4885PKM 4240/4885ALPI 3006/4885 |
| US-12077611-B2 | Cyclic peptides multimers targeting α4β7 integrin | ITGB7, ITGB4, ITGA4 | SLC7A5 2076/4885PKM 3336/4885ALPI 3864/4885 |
| US-20240425584-A1 | MECHANICALLY INTERLOCKING COMPLEXES | FCGR3B, FCGR2A, FCGRT | SLC7A5 2742/4885PKM 3560/4885ALPI 4028/4885 |
| US-20230406884-A1 | CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN | ITGB7, ITGB4, ITGA4 | SLC7A5 2407/4885PKM 3794/4885ALPI 3773/4885 |
| US-12590137-B2 | Meditope-enabled T cells | CD4, ICOS, CD40 | SLC7A5 708/4885PKM 3225/4885ALPI 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.